At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 119 enrolled
Drug / intervention
Irinotecan Liposome Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Irinotecan Liposome Injection in Patients With Advanced Breast Cancer
In Brief
A Phase 1 clinical trial evaluating Irinotecan Liposome Injection for Advanced Breast Cancer. Completed, enrolled 119 participants across 1 site.
Detailed Summary
This study is an open-label, single-arm, phase I study of irinotecan liposome injection in patients with advanced breast cancer. The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of irinotecan liposome injection in patients with advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartMay 2021
Primary CompletionJun 2023
Study CompletionJun 2024
TodayJul 2026
First PostedJan 28, 2021
Enrollment StartMay 31, 2021
Primary CompletionJun 5, 2023
Study CompletionJun 5, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.4 years ago
Interventions
Irinotecan Liposome Injectiondrug
Irinotecan Liposome Injection